Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10,507 result(s) found for: Blood Disease. Displaying page 92 of 526.
    «« First « Previous 88  89  90  91  92  93  94  95  96  Next» Last»»
    EudraCT Number: 2013-003997-28 Sponsor Protocol Number: GENA-15 Start Date*: 2014-01-15
    Sponsor Name:Octapharma Pharmazeutika Produktions GmbH,
    Full Title: Extension Study for Patients who completed GENA-05 (NuProtect) – to Investigate Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII
    Medical condition: Severe Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: GB (Completed) DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003533-24 Sponsor Protocol Number: CA182033 Start Date*: 2009-04-29
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study) Pharmacogeneti...
    Medical condition: advanced hepatocellular carcinoma /////////// Carcinoma Hepatocelular avanzado
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-002491-14 Sponsor Protocol Number: Sepsis_IFNg Start Date*: 2012-11-08
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: The effects of interferon-gamma on sepsis-induced immunoparalysis, a randomised double-blind placebo-controlled pilot (Phase IIIb) study
    Medical condition: Sepsis-induced immunoparalysis (SIRS, Sepsis, Septic shock)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10018065 - General disorders and administration site conditions 10062357 SIRS LLT
    14.1 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    14.1 10021881 - Infections and infestations 10040047 Sepsis PT
    14.1 10021428 - Immune system disorders 10061598 Immunodeficiency PT
    14.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002176-41 Sponsor Protocol Number: 17HH4268 Start Date*: 2019-09-03
    Sponsor Name:Imperial College of Science Technology and Medicine
    Full Title: PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)
    Medical condition: Ischaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    20.0 100000004849 10034039 Paroxysmal atrial fibrillation LLT
    20.0 100000004849 10066551 Chronic atrial fibrillation LLT
    20.0 100000004849 10071668 Permanent atrial fibrillation LLT
    22.1 100000004852 10057613 Thromboembolic stroke LLT
    21.1 100000004852 10022754 Intracerebral hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000880-34 Sponsor Protocol Number: 207489 Start Date*: 2017-10-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001006-18 Sponsor Protocol Number: D5136C00007 Start Date*: 2014-08-27
    Sponsor Name:AstraZeneca AB
    Full Title: Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controll...
    Medical condition: Investigation of platelet aggregation in paediatric patients with sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10040644 Sickle cell disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000372-29 Sponsor Protocol Number: JBT101-SSc-002 Start Date*: 2018-03-20
    Sponsor Name:Corbus pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
    Medical condition: Systemic Sclerosis (SSc)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10012977 Diffuse systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003506-27 Sponsor Protocol Number: BILA-3312/PED Start Date*: 2013-01-25
    Sponsor Name:FAES FARMA, S.A.
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and tolerability of 10 mg once daily bilastine in children from 2 to 11 years of age with e...
    Medical condition: Allergic Rhinoconjunctivitis and Chronic Urticaria
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PT (Completed) PL (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004901-27 Sponsor Protocol Number: HA007 Start Date*: 2006-05-24
    Sponsor Name:Nuvelo
    Full Title: A Phase 3, Multicenter, Multi-national, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects with Acute Peripheral Arterial Occlusion (N...
    Medical condition: Acute Peripheral Arterial Occlusion (acute PAO) is to peripheral vascular disease what acute coronary syndromes are to atherosclerotic heart disease and what stroke is to atherosclerotic cerebrovas...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) DK (Completed) HU (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002687-25 Sponsor Protocol Number: PHYSCA-1 Start Date*: 2011-11-16
    Sponsor Name:University Hospital of Wuerzburg
    Full Title: Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency (PHYSCA-Trial)
    Medical condition: Adrenal insufficiency under chronic glucocorticoid replacement
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10001130 Addison's disease PT
    14.0 10014698 - Endocrine disorders 10052381 Primary adrenal insufficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023211-34 Sponsor Protocol Number: Start Date*: 2011-04-27
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: Randomized Controlled Trial Comparing Intracoronary Administration of Adenosine or Sodium Nitroprusside to Control for Attenuation of Microvascular Obstruction During Primary Percutaneous Coronary ...
    Medical condition: Acute ST-segment Elevation Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10041894 ST segment elevation LLT
    14.1 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003653-26 Sponsor Protocol Number: OVG2011/07 Start Date*: 2011-12-08
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A phase II, single-centre, randomised, single-blind, study to evaluate Vi-CRM197 against historical unvaccinated controls in a healthy adult challenge model, with a Vi-PS vaccine control arm.
    Medical condition: Prophylaxis for Salmonella enterica serovar Typhi (S. Typhi) disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10039446 Salmonella typhi infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003612-45 Sponsor Protocol Number: A9001502 Start Date*: 2019-09-06
    Sponsor Name:Pfizer Inc.
    Full Title: TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001164-30 Sponsor Protocol Number: TAS-120-201 Start Date*: 2019-11-22
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
    Medical condition: Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001828-22 Sponsor Protocol Number: 101 Start Date*: Information not available in EudraCT
    Sponsor Name:Y-mAbs Therapeutics A/S
    Full Title: A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
    Medical condition: Treatment of pediatric neuroblastoma patients with CNS relapse as evidenced by CNS/LM metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073130 Central nervous system neuroblastoma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-000268-17 Sponsor Protocol Number: CC-4047-MM-007 Start Date*: 2015-04-02
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJEC...
    Medical condition: relapsed or refractory multiple myeloma (MM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NO (Completed) DK (Completed) SE (Completed) FI (Completed) ES (Completed) PT (Completed) AT (Completed) PL (Completed) GR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002556-77 Sponsor Protocol Number: MT-1303-E13 Start Date*: 2014-11-27
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT 1303 in Subjects with Moderate to Severe Act...
    Medical condition: Subjects with moderate to severe crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) NL (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004287-26 Sponsor Protocol Number: 5F9009 Start Date*: 2021-05-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplas...
    Medical condition: Intermediate/high/very high risk myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) BE (Completed) IE (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) NO (Prematurely Ended) FI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000470-78 Sponsor Protocol Number: TRA102537 Start Date*: 2006-10-30
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administe...
    Medical condition: Idiopathic thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) SK (Completed) DE (Completed) GR (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005287-60 Sponsor Protocol Number: GBT2104-132 Start Date*: 2021-11-10
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso occlusive Crises
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 88  89  90  91  92  93  94  95  96  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 07:27:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA